Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This study highlights the genetic complexities in alopecia areata, emphasizing the role of microRNAs and their association with other immune-related diseases, which could inform targeted treatment strategies.

This study found that in patients with alopecia areata, trichoscopy was a valuable tool for monitoring disease activity, severity, and therapeutic response, showing changes in trichoscopic markers that preceded improvements observed in the hair pull test.

This review explored recent research on the immune mechanisms and potential therapeutic targets for alopecia areata, highlighting the roles of immune-related cells, autocrine and paracrine signaling, as well as factors like adipose-derived stem cells and gut microbiota in disease pathogenesis.

In this observational study, researchers found that new users of tirzepatide experienced a higher incidence of alopecia compared to semaglutide users over a 12-month period, with increased risk persisting even when accounting for achieved weight loss and treatment duration.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

In this prospective study, 15 patients with patchy alopecia areata treated with intralesional methotrexate every two weeks showed a significant improvement in hair regrowth and reduction in lesion severity, with changes linked to decreased tissue levels of TNF-α.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This review article discusses recent advances in stem cell-based therapies for Alopecia Areata, noting preliminary clinical trials show significant hair regrowth, but emphasizes the need for thorough evaluation of long-term safety and efficacy.

In this observational study, among 135 Italian outpatients with alopecia areata, OCD symptoms were prevalent in 18.5%, and emotional distress was found in 20.7%, with emotional distress mediating the relationship between illness perceptions and OCD symptomatology.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This study found a strong positive correlation between alopecia areata burden and the Socio-Demographic Index, indicating a disproportionate impact on high-income countries, especially affecting young adults and females.

This review highlights that although advancements in alopecia areata treatments, such as Janus kinase inhibitors and combination therapies, show promise, further research is necessary to validate their long-term safety and efficacy.

This analysis found that females have a higher lifetime risk of alopecia areata across various regions and time periods, with increased risk associated with higher socio-demographic index levels.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.

This study found that patients with patchy alopecia areata had significantly higher serum levels of pro-inflammatory cytokines IL-6, TNF-α, IL-17A, and IL-21 compared to healthy controls, with these levels correlating positively with disease severity, age, and disease duration.

This study formulated a minoxidil nanoemulgel with improved solubilization and skin penetration, demonstrating a high entrapment efficiency and sustained drug release in vitro, which suggests potential improvements in treating androgenetic alopecia compared to conventional formulations.

This review reports that while current treatments for non-scarring alopecia, like minoxidil and finasteride, have limited efficacy due to side effects, natural remedies may offer more effective management with potentially fewer side effects, though their varying safety profiles call for further investigation.

In this study, AA patients and healthy controls showed no significant difference in carotid intima-media thickness, but AA patients had higher diastolic blood pressure and fasting blood glucose levels, indicating potential cardiovascular risks.

In this case report, a 56-year-old Black man experienced patchy scalp hair loss which began four months after his second COVID-19 vaccination, also considering his medical history of hypertension and type 2 diabetes.

In this study, trichoscopy was identified as a valuable diagnostic tool for alopecia areata, revealing that specific hair features like yellow dots and short vellus hairs help assess disease activity and phase, with diagnosis relying on multiple combined signs rather than a single indicator.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

This study reviewed recent literature and reported that although PRP products are recognized for benefits in dermatology, including wound care and hair growth, there remains a need for standardized protocols and consensus to enhance their acceptance in cosmetic dermatology.

This review summarizes recent advancements in using exosomes for promoting hair growth, finding that exosomes from various cells, like dermal papilla and mesenchymal stem cells, show promise as a potential new treatment route for alopecia.

In this case report, the authors describe a rare association of alopecia universalis with frequently relapsing nephrotic syndrome in a 3-year-old girl, suggesting a possible genetic and immune-related cause, and note that tofacitinib treatment was ineffective in her case.

This review highlights that alopecia areata, a common type of hair loss, currently lacks preventive or curative treatments, and traditional therapies such as minoxidil and corticosteroids offer inconsistent results, necessitating patient-consensual treatment planning.

This review discusses the unmet needs and barriers in managing alopecia areata in Latin America, highlighting access constraints and recommending coordinated efforts to improve patient outcomes with promising new treatments.

This study reports that topical pumpkin seed oil and sesame oil were both effective in treating alopecia areata, with no significant difference in effectiveness between the two after three months.